tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KLRS Stock Latest News

Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
Weekend UpdatesVizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
22d ago
BRO
ANNX
Kalaris Therapeutics initiated with a Buy at Chardan
PremiumThe Fly
Kalaris Therapeutics initiated with a Buy at Chardan
26d ago
KLRS
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
PremiumRatings
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
27d ago
KLRS
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
PremiumCompany Announcements
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
1M ago
8K
KLRS
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
PremiumThe Fly
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
1M ago
KLRS
Kalaris Therapeutics announces $50M private placement
PremiumThe FlyKalaris Therapeutics announces $50M private placement
1M ago
KLRS
Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
Premium
The Fly
Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
1M ago
KLRS
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
Premium
Company Announcements
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
1M ago
8K
KLRS
Kalaris Therapeutics announces initial data from TH103 trial
PremiumThe Fly
Kalaris Therapeutics announces initial data from TH103 trial
1M ago
KLRS
Kalaris Therapeutics Reports Q3 2025 Financial Progress
PremiumCompany Announcements
Kalaris Therapeutics Reports Q3 2025 Financial Progress
2M ago
KLRS
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
PremiumRatings
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
2M ago
KLRS
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
PremiumThe Fly
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
2M ago
KLRS
Kalaris Therapeutics Appoints New CFO Matthew Gall
PremiumCompany AnnouncementsKalaris Therapeutics Appoints New CFO Matthew Gall
3M ago
8K
KLRS
Kalaris Therapeutics appoints Gall as Chief Financial Officer
Premium
The Fly
Kalaris Therapeutics appoints Gall as Chief Financial Officer
3M ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
Premium
The Fly
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
3M ago
KLRS
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
PremiumRatings
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
4M ago
KLRS
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
PremiumThe Fly
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
4M ago
KLRS
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
PremiumThe Fly
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
5M ago
KLRS
Kalaris Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Kalaris Therapeutics Reports Q2 2025 Financial Results
5M ago
KLRS
Kalaris Therapeutics Elects New Directors at Annual Meeting
PremiumCompany AnnouncementsKalaris Therapeutics Elects New Directors at Annual Meeting
5M ago
8K
KLRS
Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
Premium
The Fly
Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
5M ago
KLRS
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
Premium
The Fly
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
6M ago
KLRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >